Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study by Louis Talay, Matt Vickers

Subjects: Get full text

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial by Jelena Petković-Dabić, Ivana Binić, Bojana Carić, Ljiljana Božić, Sanja Umičević-Šipka, Nataša Bednarčuk, Saša Dabić, Mirna Šitum, Snježana Popović-Pejičić, Miloš P. Stojiljković, Ranko Škrbić

Subjects: Get full text

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy by Fernando K. Malerbi, Marcello C. Bertoluci

Subjects: Get full text

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity by Andrew Overholser, Eric Czech, Linda Speer, Joel Wilson, Alex Overholser

Subjects: Get full text

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review by Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek

Subjects: Get full text

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study by Hiroya Kitsunai, Yuka Shinozaki, Sho Furusawa, Naoyuki Kitao, Miki Ito, Hiroyoshi Kurihara, Chiho Oba-Yamamoto, Jun Takeuchi, Akinobu Nakamura, Yumi Takiyama, Hiroshi Nomoto

Subjects: Get full text

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review by Andrijana Koceva, Andrijana Koceva, Katarina Mlekuš Kozamernik, Katarina Mlekuš Kozamernik, Andrej Janež, Andrej Janež, Rok Herman, Rok Herman, Simona Ferjan, Simona Ferjan, Mojca Jensterle, Mojca Jensterle

Subjects: Get full text

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition by Shasha Tian, Saijun Zhou, Weixi Wu, Yao lin, Tongdan Wang, Haizhen Sun, A‐Shan‐Jiang A‐Ni‐Wan, Yaru Li, Chongyang Wang, Xiaogang Li, Pei Yu, Yanjun Zhao

Subjects: Get full text

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence by Srikanth Krishnan, Pratyaksh K. Srivastava, Jayram Attaluri, Rebecca Nayeri, Dhananjay Chatterjee, Jay Patel, Ali Nsair, Matthew Budoff, Arash Nayeri

Subjects: Get full text

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes by Jakob Grauslund, Andreas Abou Taha, Laleh Dehghani Molander, Ryo Kawasaki, Sören Möller, Kurt Højlund, Lonny Stokholm

Subjects: Get full text

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report by Elisa Dinoi, Giuseppe Daniele, Giuseppe Daniele, Angela Michelucci, Fulvia Baldinotti, Fabrizio Campi, Piero Marchetti, Stefano Del Prato, Angela Dardano, Angela Dardano

Subjects: Get full text

The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (H... by Darshan Hullon, Ghasaq K. Subeh, Yelizaveta Volkova, Karolina Janiec, Adam Trach, Ruslan Mnevets

Subjects: Get full text

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus by Alexander C. Martins, Beatriz G. de la Torre, Fernando Albericio

Subjects: Get full text